SCHEMBL3608672

SCHEMBL3608672

CC(C=CC1=Cc2cc(-c3ccccc3)ccc2OC1)=CC(=O)O

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAOB P27338 4/20 0.47
ALOX5 P09917 2/20 0.47
PTGS1 P23219 10/20 0.43
PTGS2 P35354 10/20 0.43
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
MAPT P10636 2/20 0.38
PKM P14618 1/20 0.38
HTT P42858 1/20 0.38
RXRA P19793 2/20 0.37
RARB P10826 1/20 0.37
RARG P13631 1/20 0.37
RXRB P28702 1/20 0.36
RXRG P48443 1/20 0.36
POLB P06746 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3608669 1.00 MAOB (0.47) MAOBALOX5PTGS1PTGS2KDM4E
SCHEMBL13316590 0.87 MAOB (0.44) MAOBALOX5PTGS1PTGS2KDM4E
SCHEMBL3596089 0.86 PTGS1 (0.57) MAOBALOX5PTGS1PTGS2KDM4E
SCHEMBL3596085 0.86 PTGS1 (0.57) MAOBALOX5PTGS1PTGS2KDM4E
SCHEMBL3607979 0.86 PTGS1 (0.57) MAOBALOX5PTGS1PTGS2KDM4E
SCHEMBL13316588 0.85 MAOB (0.47) MAOBPTGS1PTGS2KDM4EALDH1A1
SCHEMBL9157430 0.81 ALOX5 (0.48) MAOBALOX5PTGS1PTGS2KDM4E
SCHEMBL9157439 0.81 ALOX5 (0.48) MAOBALOX5PTGS1PTGS2KDM4E
SCHEMBL8550221 0.81 RXRA (0.47) MAOBALOX5RXRARARBRARG
SCHEMBL8544569 0.81 RXRA (0.47) MAOBALOX5RXRARARBRARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160410-A1 USE OF PENTADIENOIC ACID DERIVATIVES FOR THE TREATMENT OF HYPERURICEMIA BOIZEL ROBERT 2010-06-24 US claimed
US-20070099854-A1 Use of pentadienoic acid derivatives for the treatment of hyperuricemia MERCK PATENT GMBH (DE) 2007-05-03 US claimed
US-20100160410-A1 USE OF PENTADIENOIC ACID DERIVATIVES FOR THE TREATMENT OF HYPERURICEMIA BOIZEL ROBERT 2010-06-24 US disclosed
US-20070099854-A1 Use of pentadienoic acid derivatives for the treatment of hyperuricemia MERCK PATENT GMBH (DE) 2007-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099854-A1 Use of pentadienoic acid derivatives for the treatment of hyperuricemia XDH, URB2, ALOX12 MAOB 1082/4885ALOX5 7/4885PTGS1 116/4885
US-20100160410-A1 USE OF PENTADIENOIC ACID DERIVATIVES FOR THE TREATMENT OF HYPERURICEMIA XDH, URB2, ALOX12 MAOB 1082/4885ALOX5 7/4885PTGS1 116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.